Should we be Using Provenge Earlier Than We Currently Do?

Sipuleucel-T (Provenge) is FDA approved after a man becomes castrate resistant. In clinical trials it has shown that it extends life when compared to placebo. The use of Provenge has raised many questions, the two most common ones are why PSA and disease progression continues while receiving this treatment (see post at for an explanation) [...]

Dealing with Influenza While Fighting Advanced Prostate Cancer

Fall is quickly approaching, along with the colors it also brings the influenza. For most people influenza is a bother, but for cancer survivors it brings many unique concerns not shared with the general population. It brings serious illness, hospitalizations and possibly death! During an influenza epidemic, between 21% and 33% of cancer survivors who [...]

Provenge, Better Survival Than Reported and a Better Economic Value for Men with Advanced Prostate Cancer

One of the constant complaints I hear fro men with advanced prostate cancer that has become castrate resistant about Provenge (sipuleucel-T) is that the anticipated increase in overall survival is only 4.1 months and given the cost of $93,000 for the three infusions many men feel that cost does not justify the survival benefit. My [...]

Dendreon Opens It First Clinical Trial in the European Union

On September 27th Dendreon announced that it has enrolled and started its first patient with metastatic advanced prostate cancer that is castrate resistanr in a European Union based clinical trial of Provenge. Finally, men in the EU can hope that in the near future that Provenge could become available to them. The trial is hoped [...]

African American Men With Advanced Prostate Cancer May Gain Significant Benefit From Provenge (Sipuleucel-T)

A subgroup analysis of the phase III trials of Provenge (Sipuleucel-T) suggests that there might be a dramatic role for Provenge in African-American men who have advanced prostate cancer that has become castration-resistant (mCRPC). The analysis, which was released at the American Urological Association 2012 Annual Scientific Meeting, was headed up by Colonel David G. [...]

A Possible Provenge Private Insurance Hitch In Men with Advanced Prostate Cancer

At a recent meeting that I attended it was reported by a nurse that one of her patients with advanced prostate cancer with only a PSA recurrence and lymph node involvement on a scan was rejected by their insurance company for reimbursement for Provenge. The insurance company indicated that to pay for the treatment they [...]

Provenge and the Concern about a Rising PSA

There has been an on-going debate on the advanced prostate cancer on-line support group about the issue of the efficacy of Provenge in light of the expectation of a person's increasing PSA number while getting the treatment. For many men with advanced prostate cancer this is a reason they elect to pass on this treatment [...]

At the AUA Meeting – Does Provenge Provide Better Survival Numbers?

The recent AUA meetings in Atlanta had a number of interesting abstracts presented that concern men with advanced prostate cancer. Some of the more interesting abstracts were look back analysis of sipuleucel-T (Provenge) done by consultants for Dendreon, the company who manufactures Provenge. They took the data from the al three of the phase III [...]

New Data Indicates That Provenge Works Best In Men With Lower PSA Scores

Today, May 16, 2012, Dendreon, the makers of Provenge, disclosed a new analysis of data of its pivotal 512-patient study of men with castrate resistant prostate cancer who received sipuleucel-T (Provenge). The new analysis separated the men in the study into four quartiles based on their prostate-specific antigen (PSA) scores. The initial design of the [...]

What Is The Actual Survival Advantage for Men Who Take Provenge? It’s Longer Than We Thought!

Understanding and deciding on appropriate treatments for men with advanced prostate cancer can be confusing. All the treatments come with side effects and one never knows what the benefits might be for an individual. Even with good clinical trials, men with advanced prostate cancer still need to navigate a most unclear path. Provenge, ever since [...]

Go to Top